Current Report Filing (8-k)
September 05 2017 - 4:01PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
August 30, 2017
ORAMED
PHARMACEUTICALS INC.
|
(Exact
name of registrant as specified in its charter)
|
DELAWARE
|
|
001-35813
|
|
98-0376008
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
Hi-Tech
Park 2/4 Givat Ram, PO Box 39098,
Jerusalem, Israel
|
|
91390
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
+972-2-566-0001
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.07. Submission of Matters to a Vote of Security Holders.
On
August 30, 2017, Oramed Pharmaceuticals Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders. The
final voting results are set forth below.
Stockholders
voted on the following proposals:
Proposal
No. 1 — Re-election of Directors.
The
stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and
until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were
as follows:
Director
Name
|
|
For
|
|
|
Against
|
|
|
Abstain
|
|
|
Broker
Non-Votes
|
|
Miriam Kidron
|
|
|
4,501,507
|
|
|
|
165,409
|
|
|
|
21,183
|
|
|
|
3,856,779
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nadav Kidron
|
|
|
4,558,261
|
|
|
|
108,655
|
|
|
|
21,183
|
|
|
|
3,856,779
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aviad Friedman
|
|
|
4,638,735
|
|
|
|
30,399
|
|
|
|
18,965
|
|
|
|
3,856,779
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Xiaopeng Li
|
|
|
4,493,283
|
|
|
|
164,653
|
|
|
|
30,163
|
|
|
|
3,856,779
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kevin Rakin
|
|
|
4,639,275
|
|
|
|
20,413
|
|
|
|
28,411
|
|
|
|
3,856,779
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Leonard Sank
|
|
|
4,635,371
|
|
|
|
24,863
|
|
|
|
27,865
|
|
|
|
3,856,779
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Slager
|
|
|
4,639,890
|
|
|
|
19,763
|
|
|
|
28,446
|
|
|
|
3,856,779
|
|
Proposal
No. 2 — Ratification of the Amendment to the Company’s Certificate of Incorporation.
The
stockholders ratified the amendment to the Company’s Certificate of Incorporation filed on July 25, 2014 to increase the
Company’s authorized common stock from 16,666,667 to 30,000,000 shares. The votes were as follows:
For
|
|
Against
|
|
Abstain
|
|
Broker
Non-Votes
|
|
|
|
|
|
|
|
7,895,809
|
|
563,265
|
|
85,804
|
|
N/A
|
Proposal
No. 3 — Ratification of Auditors.
The
stockholders ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers
International Limited, as the independent registered public accounting firm of the Company for the fiscal year ending August 31,
2017. The votes were as follows:
For
|
|
Against
|
|
Abstain
|
|
Broker
Non-Votes
|
|
|
|
|
|
|
|
8,408,650
|
|
100,264
|
|
35,964
|
|
N/A
|
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ORAMED PHARMACEUTICALS INC.
|
|
|
|
|
By:
|
/s/ Nadav Kidron
|
|
Name:
|
Nadav Kidron
|
|
Title:
|
President and CEO
|
September
5, 2017
3
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Apr 2023 to Apr 2024